Gastroenterology Research and Practice最新文献

{"title":"S1 Guideline of the German Society for Neurogastroenterology and Motility (DGNM) on Functional Dyspepsia (FD), a Disorder of Gut-Brain Interaction (DGBI) [English Language Edition].","authors":"M Storr, V Andresen, T Frieling, J M Gschossmann, J Keller, J Langhorst, C Pehl, A Stengel, J Tebbe, K Wiemer, A Madisch, M Stengel","doi":"10.1155/grp/2610765","DOIUrl":"https://doi.org/10.1155/grp/2610765","url":null,"abstract":"<p><p>Functional dyspepsia (FD) is common and classified as a disorder of gut-brain interaction (DGBI). The prevalence is estimated around 10% of the population. Diagnosis is based on symptoms, which are classified according to the Rome IV criteria, in combination with diagnostic procedures that may include laboratory testing, <i>Helicobacter pylori</i> testing, upper gastrointestinal endoscopy, abdominal ultrasound, and other examinations, depending on the severity, duration, and presence of alarm symptoms. Therapeutic procedures include psychoeducation, dietary counseling, mind-body procedures, psychotherapy, and medication. The S1 guideline summarizes the current state of knowledge and allows a targeted approach based on the currently available medical evidence.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"2610765"},"PeriodicalIF":1.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the Risk Factors for Short-Term Outcomes in Acute Small Bowel Obstruction: A Retrospective Study.","authors":"Yong Cai, Wei-Xuan Xu, Can-Hong Zhan, Qi-Hong Zhong, Shuai Chen, Hui Wang, Peng-Sheng Tu, Wen-Xuan Chen, Xian-Qiang Chen, Jun-Rong Zhang","doi":"10.1155/grp/8871353","DOIUrl":"https://doi.org/10.1155/grp/8871353","url":null,"abstract":"<p><strong>Background: </strong>As the lack of analysis on risk factors for the short-term outcomes of acute small bowel obstruction (ASBO), the current high readmission rate and severe postoperative complications of ASBO seriously affect the quality of life of patients. Risk-scoring models for evaluating the short-term outcomes of ASBO are still urgently needed.</p><p><strong>Methods: </strong>A total of 278 patients diagnosed with complete ASBO were included in this study. Cox proportional hazards regression analysis was used to construct predictive models for the length of stay (LOS) and the length of short-term recurrence (LOR). The receiver operating characteristic (ROC) curves and the area under the curve (AUC) were calculated to assess the performance.</p><p><strong>Results: </strong>The mean LOS of 278 patients was 11.19 days, and 17 patients (6.1%) were readmitted. Multivariate analysis showed that longer duration of disease (Hazard ratio, HR = 1.551), low albumin (HR = 1.681), high lumen diameter(max) (HR = 1.477), low chlorine (HR = 1.046), and operation (HR = 7.456) were risk factors for LOS. Calcium (HR = 29.391) was an independent risk factor for LOR. Operation is not a risk factor for LOR. A risk-scoring model of LOS (RS_LOS) was constructed to predict the posttreatment recovery (AUC, 30 days = 0.859). In the high-risk group, the severe adverse events (SAE) rate reached 17.1%, exceeding 1.4% in the low-risk group. The performance of RS_LOR was also satisfactory (AUC, 12 months = 0.802). In the high-risk group, the recurrence rate reached 14.3%, nearly triple that in the low-risk group (3.4%).</p><p><strong>Conclusion: </strong>The risk-scoring models of LOS and LOR provide a comprehensive evaluation on the short-term outcomes of ASBO treatment.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"8871353"},"PeriodicalIF":1.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13140370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Features and Factors Contributing to Preoperative Misdiagnosis of Gastric Gastrointestinal Stromal Tumors: A Retrospective Analysis of 27 Cases.","authors":"Jianming Xie, Jiabin Yang, Zhilong Yan","doi":"10.1155/grp/6634495","DOIUrl":"https://doi.org/10.1155/grp/6634495","url":null,"abstract":"<p><strong>Objective: </strong>Gastrointestinal stromal tumors (GISTs) lack specific clinical manifestations and are challenging to distinguish from other gastric submucosal tumors (SMTs). This study is aimed at illustrating the atypical manifestations of non-GISTs mimicking gastric GISTs and determining whether objective preoperative factors can help differentiate gastric GISTs from non-GISTs in patients.</p><p><strong>Methods: </strong>We included 29 GIST patients and 27 patients preoperatively misdiagnosed with GIST located in the stomach. We compared demographic data and tumor characteristics based on endoscopic ultrasound (EUS) and computed tomography (CT) findings between GIST and non-GIST groups.</p><p><strong>Results: </strong>Clinical symptoms in the extragastric compressions group were significantly more common (100%) than in the GISTs group (35.7%) (<i>p</i> < 0.05). Gastrointestinal stromal tumors more commonly exhibited an exophytic growth pattern than gastric non-GISTs SMTs (<i>p</i> < 0.05). Mean arterial phase attenuation was significantly lower in gastric non-GISTs SMTs (54.3 HU) compared with GISTs (59 HU, <i>p</i> = 0.003), with an optimal cutoff value of < 28.9 HU and an AUC of 0.689. There was a significant difference in lesion size between the GIST and gastric non-GIST groups, with GISTs presenting larger lesions (4.2 vs. 3.3 cm, <i>p</i> = 0.038). Additionally, necrosis was more frequently observed in the GISTs.</p><p><strong>Conclusions: </strong>For gastric submucosal protuberant lesions, a comprehensive EUS and CT imaging examination is necessary for accurate diagnosis to avoid misdiagnosis and inappropriate treatment, which may affect patient prognosis.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"6634495"},"PeriodicalIF":1.4,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13122723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Mucosal and Faecal Microbiomes in Patients With Cirrhosis.","authors":"Caroline S Stokes, Tatjana Türk, Frank Lammert, Beate Appenrodt","doi":"10.1155/grp/6847983","DOIUrl":"https://doi.org/10.1155/grp/6847983","url":null,"abstract":"<p><strong>Objective: </strong>The colonic sigmoid mucosal microbiome is reportedly different from the faecal microbiome in patients with cirrhosis. This exploratory study is aimed at comparing the luminal and mucosal microbiome in patients with cirrhosis, with a specific focus on the proximal intestine.</p><p><strong>Methods: </strong>Mucosal and faecal samples were obtained from 12 patients with cirrhosis. The microbiome was quantified with V4 16S rRNA gene sequencing. Relative abundance, alpha and beta diversity were calculated, compared between the mucosal and faecal samples and correlated with stage of cirrhosis.</p><p><strong>Results: </strong>Faecal samples displayed lower microbial diversity than mucosal samples (Shannon diversity, p = 0.025) and the microbiome profiles differed significantly: Operational taxonomic units primarily of the phyla Firmicutes and Actinobacteria were more abundant in faecal samples, whereas biopsy samples contained units spanning all six phyla. Microbial composition of faecal samples were more similar to faecal samples from other patients rather than to the individual's corresponding biopsy sample (principal coordinate analysis, p = 0.004). At the family level, Lachnospiraceae, Erysipelotrichaceae and Enterobacteriaceae were significantly more abundant in faecal samples, whereas biopsy samples contained more Streptococcaceae (p = 0.011) and Prevotellaceae (p = 0.031). Faecal samples from patients in Child-Pugh Stage C contained less Bacteroidetes but significantly more Streptococcaceae than Stage B samples (p = 0.04); however, biopsy samples did not differ significantly.</p><p><strong>Conclusions: </strong>This exploratory study in a small sample of patients with cirrhosis observed significant differences in the microbial signature of faecal versus biopsy samples from the proximal intestine. Future studies are needed to further investigate the relationship between different gastrointestinal microbial sites and cirrhosis.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"6847983"},"PeriodicalIF":1.4,"publicationDate":"2026-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Delayed Bleeding and Its Impact on Long-Term Efficacy After Endoscopic Sclerotherapy for Internal Haemorrhoids by Inverted Colonoscopy Without Transparent Caps.","authors":"Yue Chen, Mingqiong Wang, Xing Su, Yuxia Zhu, Qin He, Mingke Li, Peng Zou, Chang Liu, Hongmei Liu, Ruizheng Zou","doi":"10.1155/grp/1777665","DOIUrl":"10.1155/grp/1777665","url":null,"abstract":"<p><strong>Background: </strong>We investigated the incidence, timing, risk factors and prognosis of delayed haemorrhage after endoscopic injection sclerotherapy (EIS) with lauromacrogol for internal haemorrhoids (IHs) using an inverted colonoscope without transparent caps.</p><p><strong>Methods: </strong>The clinical data of 252 patients undergoing EIS with lauromacrogol for IH using an inverted colonoscope without transparent caps were retrospectively analysed. Delayed haemorrhage was defined as bleeding occurring between 24 h and 1 month postoperatively. The incidence, timing and volume of delayed bleeding were recorded. Clinical risk factors were analysed, and patients were followed up for 2 years.</p><p><strong>Results: </strong>Delayed bleeding occurred in 17.5% (44/252) of patients, with a median onset of 2 (1-17) days. Among them, 97.7% (43/44) experienced < 20-mL bleeding within 9 days that resolved spontaneously; one patient developed 500-mL bleeding on postoperative Day 17. Multivariate logistic regression analysis showed that albumin < 40 g/L (odds ratio [OR]: 5.093; <i>p</i> < 0.001), triglycerides > 1.7 mmol/L (OR: 3.814, <i>p</i> < 0.001), Wexner Constipation Score ≥ 15 (OR: 5.340, <i>p</i> < 0.001) and > 4 injection sites (OR: 4.425, <i>p</i> = 0.005) were independent risk factors. The case of 500-mL bleeding may have resulted from an excessively deep injection and a high injection position. After 2 years, treatment effectiveness did not differ significantly between patients with and without delayed bleeding (<i>p</i> = 0.622).</p><p><strong>Conclusions: </strong>Delayed bleeding is a common complication after EIS with lauromacrogol for IHs using an inverted colonoscope without transparent caps. Most cases are small volume, early onset and self-limiting. Delayed bleeding does not affect long-term EIS efficacy. Risk factors include hypertriglyceridaemia, hypoproteinaemia, postoperative constipation and > 4 injection sites. As delayed massive bleeding may occur when injections are too deep or positioned too high, EIS should be performed cautiously. Adherence to guidelines, including the use of a transparent cap or forward-view endoscopy, is recommended.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"1777665"},"PeriodicalIF":1.4,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Key Targets of Herbal Compounds for Liver Fibrosis Using Network Pharmacology Combined With Transcriptomics.","authors":"Chen Chen, Bo Huang, Mengting Hu, Shengpeng Yang, Bo Lan, Dejun Cui","doi":"10.1155/grp/9985154","DOIUrl":"https://doi.org/10.1155/grp/9985154","url":null,"abstract":"<p><p>Chinese herbal compound prescriptions have demonstrated efficacy in preventing and treating liver fibrosis (LF), though their mechanisms remained unclear. This study is aimed at identifying diagnostic biomarkers and elucidating the molecular mechanism underlying the effects of the TCM prescription on LF. LF-related datasets (GSE162694, GSE84044, and GSE136103) were obtained from a public database. Active ingredient-related target genes (AIRTGs) and LF-related target genes (LFRTGs) were intersected with differentially expressed genes (DEGs) between the LF and normal control (NC) group to select candidate genes. Subsequently, biomarkers for LF diagnosis were determined using Boruta and LASSO algorithms, receiver operating characteristic (ROC), and expression analyses. A nomogram was constructed to evaluate the capability of these biomarkers for predicting LF risk. Furthermore, GSEA and immunoinfiltration analysis were conducted, along with single-cell analysis to identify relevant cell types in LF. COL3A1 and ALOX5 were identified as diagnostic biomarkers for LF, and the nomogram was proven effective in predicting LF risk. GSEA showed that COL3A1 might play vital roles in cell growth and differentiation, extracellular matrix organization, and cell-matrix interactions. The functions of ALOX5 might be associated with cell-cell interaction, cytoskeletal regulation, and so forth. Immunoinfiltration analysis revealed that activated dendritic cells (DCs) were highly infiltrated, whereas monocytes were less infiltrated in LF. COL3A1 expression was positively correlated with monocytes, but both COL3A1 and ALOX5 showed negative correlations with activated DCs. Single-cell analysis identified nine cell types, with macrophages, B cells, and mesenchyme cells emerging as key cell types. Cell communication analysis demonstrated stronger interactions between macrophages and mesenchymal cells in the LF group. Pseudotime analysis unveiled that the expression of ALOX5 was upregulated and then downregulated, whereas that of COL3A1 was gradually downregulated during the midstage and stabilized thereafter. COL3A1 and ALOX5 may serve as biomarkers for the diagnosis and treatment of LF with Chinese herbal compound prescriptions, contributing to more accurate diagnosis and improved LF therapy.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"9985154"},"PeriodicalIF":1.4,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real-World Cohort Study.","authors":"Mukesh Kumar Ranjan, Pradeep Neupane, Bigyan Maharjan, Manoj Lamsal, Bikash Poudel","doi":"10.1155/grp/1808791","DOIUrl":"https://doi.org/10.1155/grp/1808791","url":null,"abstract":"<p><strong>Background and aim: </strong>Azathioprine is one of the commonly used maintenance therapies in patients with inflammatory bowel disease (IBD), specifically in low- and middle-income countries. However, the use of thiopurines is questioned due to safety concerns. We aimed to assess the adverse event (AE) profile of azathioprine in IBD patients.</p><p><strong>Methods: </strong>This was a single-centre retrospective study. All the consecutive patients treated with azathioprine were considered for this study. Data were collected from prospectively maintained IBD files. The primary objective was to assess the adverse events arising due to azathioprine use. The AEs were defined as per standard definitions. The relation between the AE and dose and duration of azathioprine use was assessed.</p><p><strong>Results: </strong>Among 48 patients [UC: 20 (41.7%) and CD: 28 (58.3%)] included, 30 (62.5%) were male. The mean age and the disease duration were 41.2 ± 15.7 years and 15 (5-40.5) months, respectively. The initiation and maximum dose of azathioprine were 0.91 ± 0.15 and 2.04 ± 0.58 mg/kg. The median thiopurine treatment duration was 6.5 (2.25-15), 11.5 (3.5-23.5) and 5.75 (2-12.5) months, respectively, in the whole cohort, UC and CD. A total of 25 (52.1%) patients developed adverse events [8 (40.0%) in UC and 17 (60.7%) in CD]. The commonest AEs were leukopenia in 15 (31.2%), GI intolerance in 5 (10.4%), arthralgia in 4 (8.3%), hepatitis in 3 (6.2%) and hair fall in 2 (4.1%) patients. No infection or acute pancreatitis episode or malignancy was reported. A total of 16 (33.3%) patients stopped azathioprine. AEs were the most common cause of azathioprine withdrawal in 12 (25.0%). No serious adverse event was reported.</p><p><strong>Conclusion: </strong>Adverse events are common and lead to therapy discontinuation in one fourth of the IBD patients on azathioprine. The commonest adverse events are leukopenia, GI intolerance, arthralgia, hepatitis, and hair fall.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"1808791"},"PeriodicalIF":1.4,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13067047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Laboratory, and Molecular Characteristics of <i>GPD1</i> Gene Variants: A Cause of Hepatomegaly and Hepatic Steatosis in Early Childhood.","authors":"Moodhi Alharbi, Ali Alasmari, Sultan Alkasim, Abdulrahman Al-Hussaini","doi":"10.1155/grp/9986415","DOIUrl":"https://doi.org/10.1155/grp/9986415","url":null,"abstract":"<p><strong>Background and objectives: </strong>Mutations in the <i>GPD1</i> gene, which encodes glycerol-3-phosphate dehydrogenase 1 (GPD1), are a rare cause of monogenic hypertriglyceridemia (HTG) during childhood. This study is aimed at providing a detailed analysis of the clinical, laboratory, and molecular characteristics of all patients affected by biallelic <i>GPD1</i> gene variants, including three cases from our center.</p><p><strong>Methods: </strong>A literature search was conducted across the English MEDLINE, PubMed, and Embase databases from 1966 to 2023 for the studies that reported on GPD1 deficiency with confirmed <i>GPD1</i> gene variants using the search words HTG and <i>GPD1</i> gene.</p><p><strong>Results: </strong>A total of 39 children (including three from our center) were identified with 15 pathogenic mutations in <i>GPD1</i> reported in 14 articles from 5 ethnicities (15 Arabs, 14 Caucasians, 4 Chinese, 5 Indian/South Asian, and 1 Turkish): 8 missense variants (one compound heterozygous), 3 nonsense, 3 frameshifts, and 1 splicing. Three of the 15 variants likely originated from a common ancestor, \"that is, founder in nature\": p.I119fs∗94 (Palestinian Arabs), p.Gly299Arg (Czech population), and p.Thr251Asnfs∗10 (Saudi Arabia). The median age at presentation was 9 months. All patients manifested hepatomegaly, elevated transaminases, and HTG. Nineteen patients underwent liver biopsy; all showed micro- and macrosteatosis, mild to moderate portal fibrosis in 58% (11 out of 19), and cirrhosis in the remaining eight cases (42%). Follow-up data showed that HTG normalized in 28% of patients (11 out of 39) but persisted mildly in the remaining 72% (28 out of 39).</p><p><strong>Conclusion: </strong>Mutations in the <i>GPD1</i> gene should be considered in children with hepatomegaly, hepatic steatosis, and HTG. This study indicates that <i>GPD1</i> deficiency may not be a transient or benign condition, as previously considered, due to the persistence of HTG and liver pathology in a significant proportion of cases. Identifying specific GPD1 variants may expedite targeted molecular analysis.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"9986415"},"PeriodicalIF":1.4,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13063116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review on the Progress and Strategies of <i>Helicobacter pylori</i> Eradication Therapy for Patients With Penicillin Allergy.","authors":"Yuxin Zhang, Baojun Suo, Xueli Tian, Cailing Li, Xinlu Ren, Kai Zhou, Changmin Mi, Yuxin Wang, Lingling Ma, Liya Zhou, Zhiqiang Song","doi":"10.1155/grp/5587248","DOIUrl":"https://doi.org/10.1155/grp/5587248","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori (H. pylori)</i> eradication in penicillin-allergic patients poses a challenge. The currently recommended regimens are inadequate for clinical eradication therapy. Recent years have seen reports of new drugs, regimens, and study evidence in this field; yet comprehensive review articles on the treatment of <i>H. pylori</i> infection in penicillin-allergic patients are scarce.</p><p><strong>Methods: </strong>A literature search of PubMed, Web of Science, Embase, China National Knowledge Infrastructure, the China Science and Technology Journal Database, and the Wanfang Database up to January 10, 2026, was conducted with the search strategy (\"<i>Helicobacter pylori\"</i> OR <i>\"H. pylori</i>\") AND (\"treatment\" OR \"therapy\") AND (\"penicillin\" OR \"beta-lactam\") AND (\"allergy\", \"allergic\" OR \"anaphylaxis\") for both English and Chinese language publications.</p><p><strong>Results: </strong>The final literature review included 132 treatment groups from 56 studies in nine different countries or regions, with a total of 5542 patients included in the analyses. The overall eradication rates of triple regimens were unsatisfactory (72.9%, 95% CI 70.7%-75.2%). The classic quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is commonly recommended due to its relatively satisfactory efficacy and sufficient research evidence (81.4%, 95% CI 78.6%-84.2%). The mean eradication rate for other regimens containing new drugs such as minocycline, cefuroxime, sitafloxacin, vonoprazan, and rifabutin is well (> 80%).</p><p><strong>Conclusion: </strong>The classical bismuth quadruple therapy used to be the most commonly used regimen. The overall eradication efficacy of triple therapies is unacceptable. Although new drugs and regimens have emerged, their efficacy needs confirmation through more high-quality, large-scale clinical studies to identify the optimal eradication therapy regimen. Individualized treatment, particularly therapies tailored based on the results of genetic antibiotic resistance testing, represents an important direction for future research.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"5587248"},"PeriodicalIF":1.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Symptom Clusters and Core Symptoms in Inflammatory Bowel Disease: A Network Analysis in Chinese Cohorts.","authors":"Zhihang Zhong, Yu Luo, Qin Xie, Xia Xie, Rong Zhao","doi":"10.1155/grp/4038190","DOIUrl":"https://doi.org/10.1155/grp/4038190","url":null,"abstract":"<p><strong>Background: </strong>Research on symptom clustering in patients with inflammatory bowel disease (IBD) using network analysis is limited. Core symptom clusters in Chinese patients with IBD have not been clearly defined, and comparative evidence between Crohn's disease (CD) and ulcerative colitis (UC) remains scarce, limiting the development of targeted symptom management strategies.</p><p><strong>Methods: </strong>Data were collected from three hospitals using the Chinese version of the symptom scale for IBD to assess symptom frequency, severity, and distress. Exploratory factor analysis was performed to identify symptom clusters. Symptom networks for CD and UC were constructed using JASP 0.19.1.0 to identify core and bridge symptoms. Bootstrap methods were applied to evaluate edge-weight accuracy and the stability of centrality indices.</p><p><strong>Results: </strong>Abdominal pain (78.3%) was the most prevalent symptom in patients with CD, whereas mucopurulent bloody stool (75.2%) was most common in patients with UC. Five symptom clusters were identified. In CD, diarrhea (Rs = 1.700) emerged as the core symptom, whereas diarrhea (Rb = 1.812) and abdominal pain (Rb = 1.812) functioned as bridge symptoms. In UC, weight loss (Rs = 1.421) was the core symptom, with nutritional deficiency serving as the primary bridge symptom (Rb = 1.931). Bootstrap analysis showed narrow confidence intervals for edge weights, and the stability coefficients for strength and closeness centrality exceeded 0.25, indicating robust and reliable networks.</p><p><strong>Conclusion: </strong>Five distinct symptom clusters were identified, and separate symptom networks were established for CD and UC. These findings provide evidence for disease-specific symptom prioritization and may support the development of targeted symptom management strategies.</p>","PeriodicalId":12597,"journal":{"name":"Gastroenterology Research and Practice","volume":"2026 ","pages":"4038190"},"PeriodicalIF":1.4,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13053652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}